Pss43 - Dupilumab Improves Absenteeism in Moderate-To-Severe Atopic Dermatitis Patients Compared With Placebo in Phase 3 Liberty Ad Solo Studies

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2543
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Laboratory Safety of Dupilumab in Moderate‐to‐severe Atopic Dermatitis: Results From Three Phase III Trials ( LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS )

British Journal of Dermatology
DermatologyMedicine
2019English

Dupilumab in Moderate-To-Severe Atopic Dermatitis With or Without Comorbid Food Allergy: Pooled Analysis of 2 Randomized Phase 3 Trials (LIBERTY AD SOLO 1 & 2)

Journal of Allergy and Clinical Immunology
AllergyImmunology
2018English

Dupilumab Improves Outcomes of Concurrent Asthma and Chronic Sino-Nasal Conditions in Patients With Atopic Dermatitis—a Pooled Analysis of Four Phase 3 Studies (LIBERTY AD SOLO 1 & 2, CHRONOS, and CAFÉ)

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Dupilumab Treatment Improves Quality of Life in Adult Patients With Moderate-To-Severe Atopic Dermatitis: Results From a Randomized, Placebo-Controlled Clinical Trial

British Journal of Dermatology
DermatologyMedicine
2018English

605 Efficacy and Safety of Dupilumab in Adolescent Patients With Moderate-To-Severe Atopic Dermatitis

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

615 Dupilumab Elicits Rapid and Sustained Improvements in Itch in Adults With Moderate-To-Severe Atopic Dermatitis

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

Group 2 Innate Lymphoid Cells in Patients With Severe Atopic Dermatitis on Dupilumab

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Efficacy and Safety of Dupilumab for the Treatment of Moderate-To-Severe Atopic Dermatitis in Adults

Oncotarget
Oncology
2017English

Dupilumab Improves Lung Function and Reduces Severe Exacerbation Rate in Patients With Uncontrolled, Moderate-To-Severe Asthma With or Without Comorbid Allergic Rhinitis: Results From the Phase 3 LIBERTY ASTHMA QUEST Study

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy